Biallelic BRCA Loss and Homologous Recombination Deficiency in Nonbreast/Ovarian Tumors in Germline BRCA1/2 Carriers

PURPOSE Breast and ovarian tumors in germline BRCA1/2 carriers undergo allele-specific loss of heterozygosity, resulting in homologous recombination deficiency (HRD) and sensitivity to poly-ADP-ribose polymerase (PARP) inhibitors. This study investigated whether biallelic loss and HRD also occur in primary nonbreast/ovarian tumors that arise in germline BRCA1/2 carriers. METHODS A clinically ascertained cohort of BRCA1/2 carriers with a primary nonbreast/ovarian cancer was identified, including canonical (prostate and pancreatic cancers) and noncanonical (all other) tumor types. Whole-exome sequencing or clinical sequencing results (n = 45) were analyzed. A pan-cancer analysis of nonbreast/ovarian primary tumors from germline BRCA1/2 carriers from The Cancer Genome Atlas (TCGA, n = 73) was used as a validation cohort. RESULTS Ages of nonbreast/ovarian cancer diagnosis in germline BRCA1/2 carriers were similar to controls for the majority of cancer types. Nine of 45 (20%) primary nonbreast/ovarian tumors from germline BRCA1/2 carriers had biallelic loss of BRCA1/2 in the clinical cohort, and 23 of 73 (32%) in the TCGA cohort. In the combined cohort, 35% and 27% of primary canonical and noncanonical BRCA tumor types, respectively, had biallelic loss. High HRD scores (HRDex > 42) were detected in 81% of tumors with biallelic BRCA loss compared with 22% (P < .001) of tumors without biallelic BRCA loss. No differences in genomic profile, including mutational signatures, mutation spectrum, tumor mutational burden, or microsatellite instability, were found in primary nonbreast/ovarian tumors with or without biallelic BRCA1/2 loss. CONCLUSION A proportion of noncanonical primary tumors have biallelic loss and evidence of HRD. Our data suggest that assessment of biallelic loss and HRD could supplement identification of germline BRCA1/2 mutations in selection of patients for platinum or PARP inhibitor therapy.

[1]  K. Maxwell,et al.  Gastric Cancer Risk and Pathogenesis in BRCA1 and BRCA2 Carriers , 2022, Cancers.

[2]  G. Sirugo,et al.  The Penn Medicine BioBank: Towards a Genomics-Enabled Learning Healthcare System to Accelerate Precision Medicine in a Diverse Population , 2022, Journal of personalized medicine.

[3]  M. Galsky,et al.  Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors , 2022, JAMA oncology.

[4]  M. Ladanyi,et al.  Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of “Second Hit” in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma , 2022, Molecular Diagnosis & Therapy.

[5]  S. Culine,et al.  Characterization of lung cancers in patients with BRCA germline variants: A multicenter series. , 2022, Lung cancer.

[6]  D. Rader,et al.  Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer , 2021, European urology.

[7]  J. Pluta,et al.  Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers , 2021, Nature Communications.

[8]  R. Berger,et al.  Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. , 2021, Gastroenterology.

[9]  Cun-Yu Wang,et al.  Recent advancements in PARP inhibitors-based targeted cancer therapy , 2020, Precision clinical medicine.

[10]  J. Pearson,et al.  Using whole-genome sequencing data to derive the homologous recombination deficiency scores , 2020, npj Breast Cancer.

[11]  J. Martens,et al.  Pan-cancer landscape of homologous recombination deficiency , 2020, Nature Communications.

[12]  A. Venkitaraman.  How do mutations affecting the breast cancer genes BRCA1 and BRCA2 cause cancer susceptibility? , 2019, DNA repair.

[13]  Dustin N. Hartzel,et al.  A genome-first approach to aggregating rare genetic variants in LMNA for association with electronic health record phenotypes , 2019, Genetics in Medicine.

[14]  N. Socci,et al.  Tumour lineage shapes BRCA-mediated phenotypes , 2019, Nature.

[15]  Steven J. M. Jones,et al.  Pathogenic Germline Variants in 10,389 Adult Cancers. , 2018, Cell.

[16]  E. Friedman,et al.  Phenotypic characteristics of colorectal cancer in BRCA1/2 mutation carriers , 2018, European Journal of Human Genetics.

[17]  Nancy R. Zhang,et al.  BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers , 2017, Nature Communications.

[18]  Z. Liang,et al.  Impact of germline and somatic BRCA1/2 mutations: tumor spectrum and detection platforms , 2017, Gene Therapy.

[19]  Alan Ashworth,et al.  PARP inhibitors: Synthetic lethality in the clinic , 2017, Science.

[20]  B. Taylor,et al.  deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution , 2016, Genome Biology.

[21]  Alan Ashworth,et al.  BRCAness revisited , 2016, Nature Reviews Cancer.

[22]  Alexander Gutin,et al.  Association of BRCA1/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes , 2014, Breast Cancer Research.

[23]  Nicolai J. Birkbak,et al.  Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Kai Ye,et al.  MSIsensor: microsatellite instability detection using paired tumor-normal sequence data , 2014, Bioinform..

[25]  E. Friedman,et al.  Cancer risks among BRCA1 and BRCA2 mutation carriers , 2007, British Journal of Cancer.

[26]  S. Powell,et al.  Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation , 2003, Oncogene.

[27]  OUP accepted manuscript , 2022, The Oncologist.